Delphi has acted as legal advisor to Fluicell AB (publ) in connection to a rights issue of 32,7 MSEK and listing on Nasdaq First North. The first day of trade is April 18.
Fluicell is based in Gothenburg Sweden and the company has commercialized a product portfolio to study single cells, primarily in the field of drug development. Fluicell’s existing products are the research tools Biopen® and Dynaflow® Resolve, which today allow researchers to investigate the effects of drugs on individual cells at a unique level of detail. As a further development of Fluicell’s existing product portfolio, the company is developing a unique high-resolution bioprinting technology in both 2D and 3D under the name Biopixlar™ Retina. With this system, complex tissue-like structures can be created where positioning of individual cells can be controlled. More information about the company is found on http://fluicell.com.
The Delphi team mainly consisted of Andreas Wirén (Partner), Daniel Jessen Winbo (Senior Associate) and Anders Hulegårdh (Partner).
Delphi is one of the top commercial law firms in Sweden. We help our clients with mergers and acquisitions. We advise them on matters of banking, finance and capital markets. We represent clients in court and in arbitration and are acknowledged as being extremely competent in public procurement, environmental law and real estate law.
Many of us are specialists in high-tech fields such as IT, intellectual property and life science. Our drive and our interest in technology and business probably explain, in part, our success. We are often praised for our commercial sense and our ability to understand the client’s business.
Our clients are to be found primarily in Scandinavia, Europe and North America. We also co-operate with law firms globally and regularly assist clients on international matters. We have a total workforce of approximately 185, of which more than 120 are lawyers. We have offices in Stockholm, Göteborg, Malmö, Linköping and Norrköping.